Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

被引：32

作者：

Burdett, Nikki L. ^{[1
,2
,3
]}

Willis, Madelynne O. ^{[1
]}

Alsop, Kathryn ^{[1
,2
]}

Hunt, Allison L. ^{[4
,5
,6
]}

Pandey, Ahwan ^{[1
]}

Hamilton, Phineas T. ^{[7
]}

Abulez, Tamara ^{[5
,6
,8
]}

Liu, Xuan ^{[9
]}

Hoang, Therese ^{[1
]}

Craig, Stuart ^{[1
]}

Fereday, Sian ^{[1
,2
]}

Hendley, Joy ^{[1
]}

Garsed, Dale W. ^{[1
,2
]}

Milne, Katy ^{[7
]}

Kalaria, Shreena ^{[7
]}

Marshall, Ashley ^{[7
]}

Hood, Brian L. ^{[5
,6
,8
]}

Wilson, Katlin N. ^{[5
,6
,8
]}

Conrads, Kelly A. ^{[5
,6
,8
]}

Pishas, Kathleen, I ^{[1
,2
]}

Ananda, Sumitra ^{[1
,10
,11
,12
]}

Scott, Clare L. ^{[1
,13
]}

Antill, Yoland ^{[14
,15
,16
]}

McNally, Orla ^{[17
,18
]}

Mileshkin, Linda ^{[1
,2
]}

Hamilton, Anne ^{[1
,2
,17
]}

Au-Yeung, George ^{[1
,2
]}

Devereux, Lisa ^{[1
,2
]}

Thorne, Heather ^{[1
,2
]}

Bild, Andrea ^{[19
]}

Bateman, Nicholas W. ^{[6
,8
,20
]}

Maxwell, G. Larry ^{[4
,5
,6
,20
]}

Chang, Jeffrey T. ^{[9
]}

Conrads, Thomas P. P. ^{[5
,6
,8
,20
]}

Nelson, Brad H. ^{[7
,21
,22
]}

Bowtell, David D. L. ^{[1
,2
]}

Christie, Elizabeth L. L. ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia

[3] Eastern Hlth, Dept Med Oncol, Box Hill, Vic, Australia

[4] Womens Hlth Integrated Res Ctr, Inova Hlth Syst, Inova Womens Serv Line, Annandale, Vic, Australia

[5] Uniformed Serv Univ Hlth Sci, Gynecol Canc Ctr Excellence, Dept Obstet & Gynecol, Bethesda, MD USA

[6] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA

[7] Deeley Res Ctr, BC Canc, Victoria, BC, Canada

[8] Henry M Jackson Fdn Advancement Mil Med Inc, Bethesda, MD USA

[9] Univ Texas Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX USA

[10] Western Hlth, Dept Med Oncol, St Albans, Vic, Australia

[11] Univ Melbourne, Dept Med, Western Hlth, St Albans, Vic, Australia

[12] Epworth Healthcare, East Melbourne, Vic, Australia

[13] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia

[14] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia

[15] Cabrini Hlth, Malvern, Vic, Australia

[16] Peninsula Hlth, Dept Med Oncol, Frankston, Vic, Australia

[17] Royal Womens Hosp, Parkville, Vic, Australia

[18] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia

[19] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Monrovia, CA USA

[20] Uniformed Serv Univ Hlth Sci, John P Murtha Canc Ctr Res Program, Dept Surg, Bethesda, MD USA

[21] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada

[22] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada

来源：

NATURE GENETICS | 2023年 / 55卷 / 03期

基金：

澳大利亚国家健康与医学研究理事会; 加拿大创新基金会; 英国医学研究理事会;

关键词：

CIRCULATING TUMOR DNA; GERMLINE MUTATIONS; EVOLUTIONARY HISTORY; SOMATIC MUTATIONS; PARP INHIBITOR; GENES; RESISTANCE; SIGNATURES; REVERSION; DETERMINANTS;

D O I：

10.1038/s41588-023-01320-2

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to initial treatment, acquired resistance is common. We undertook a multiomics approach to interrogate molecular diversity in end-stage disease, using multiple autopsy samples collected from 15 women with HR-deficient HGSC. Patients had polyclonal disease, and several resistance mechanisms were identified within most patients, including reversion mutations and HR restoration by other means. We also observed frequent whole-genome duplication and global changes in immune composition with evidence of immune escape. This analysis highlights diverse evolutionary changes within HGSC that evade therapy and ultimately overwhelm individual patients. Multiple samples collected at autopsy from women with homologous recombination-deficient high-grade serous ovarian cancer highlight substantial inter- and intratumoral heterogeneity. A plethora of resistance mechanisms were identified within and between patients.

引用

页码：437 / +

页数：33

共 50 条

[1] Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor
D'Angelo, Emanuela
Espinosa, Inigo
Felicioni, Lara
Buttitta, Fiamma
Prat, Jaime
HUMAN PATHOLOGY, 2023, 141 : 15 - 21
[2] Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
Bouberhan, Sara
Philp, Lauren
Hill, Sarah
Al-Alem, Linah F.
Rueda, Bo
CANCERS, 2020, 12 (05)
[3] Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
Patel, Jai N.
Braicu, Ioana
Timms, Kirsten M.
Solimeno, Cara
Tshiaba, Placede
Reid, Julia
Lanchbury, Jerry S.
Darb-Esfahani, Silvia
Ganapathi, Mahrukh K.
Sehouli, Jalid
Ganapathi, Ram N.
BRITISH JOURNAL OF CANCER, 2018, 119 (09) : 1060 - 1066
[4] TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
Chien, Jeremy
Sicotte, Hugues
Fan, Jian-Bing
Humphray, Sean
Cunningham, Julie M.
Kalli, Kimberly R.
Oberg, Ann L.
Hart, Steven N.
Li, Ying
Davila, Jaime I.
Baheti, Saurabh
Wang, Chen
Dietmann, Sabine
Atkinson, Elizabeth J.
Asmann, Yan W.
Bell, Debra A.
Ota, Takayo
Tarabishy, Yaman
Kuang, Rui
Bibikova, Marina
Cheetham, R. Keira
Grocock, Russell J.
Swisher, Elizabeth M.
Peden, John
Bentley, David
Kocher, Jean-Pierre A.
Kaufmann, Scott H.
Hartmann, Lynn C.
Shridhar, Viji
Goode, Ellen L.
NUCLEIC ACIDS RESEARCH, 2015, 43 (14) : 6945 - 6958
[5] Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
Stiegeler, Nadja
Garsed, Dale W.
Au-Yeung, George
Bowtell, David D. L.
Heinzelmann-Schwarz, Viola
Zwimpfer, Tibor A.
FRONTIERS IN ONCOLOGY, 2024, 14
[6] High-grade serous ovarian cancer: the clone wars
Salomon-Perzynski, Aleksander
Salomon-Perzynska, Magdalena
Michalski, Bogdan
Skrzypulec-Plinta, Violetta
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2017, 295 (03) : 569 - 576
[7] A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis
Guarischi-Sousa, Rodrigo
Kroll, Jose Eduardo
Bonaldi, Adriano
Pierry, Paulo Marques
Villela, Darine
Souza, Camila Alves
Silva, Juliana Santos
Buerger, Matheus Carvalho
Oliveira, Felipe Azevedo
de Paula, Marcelo Gomes
Meliso, Fabiana Marcelino
de Almeida, Luiz Gustavo
Monfredini, Priscilla Morais
de Oliveira, Ana Gabriela
Milanezi, Fernanda
Scapulatempo-Neto, Cristovam
Yamamoto, Guilherme Lopes
DIAGNOSTICS, 2023, 13 (21)
[8] Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients
Feng, Zheng
Wen, Hao
Ju, Xingzhu
Bi, Rui
Chen, Xiaojun
Yang, Wentao
Wu, Xiaohua
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
[9] Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Pikkusaari, Sanna
Tumiati, Manuela
Virtanen, Anni
Oikkonen, Jaana
Li, Yilin
Perez-Villatoro, Fernando
Muranen, Taru
Salko, Matilda
Huhtinen, Kaisa
Kanerva, Anna
Koskela, Heidi
Tapper, Johanna
Koivisto-Korander, Riitta
Joutsiniemi, Titta
Haltia, Ulla-Maija
Lassus, Heini
Hautaniemi, Sampsa
Farkkila, Anniina
Hynninen, Johanna
Hietanen, Sakari
Carpen, Olli
Kauppi, Liisa
CLINICAL CANCER RESEARCH, 2023, 29 (16) : 3110 - 3123
[10] Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
Lee, Sanghoon
Zhao, Li
Rojas, Christine
Bateman, Nicholas W.
Yao, Hui
Lara, Olivia D.
Celestino, Joseph
Morgan, Margaret B.
Nguyen, Tri V.
Conrads, Kelly A.
Rangel, Kelly M.
Dood, Robert L.
Hajek, Richard A.
Fawcett, Gloria L.
Chu, Randy A.
Wilson, Katlin
Loffredo, Jeremy L.
Viollet, Coralie
Jazaeri, Amir A.
Dalgard, Clifton L.
Mao, Xizeng
Song, Xingzhi
Zhou, Ming
Hood, Brian L.
Banskota, Nirad
Wilkerson, Matthew D.
Te, Jerez
Soltis, Anthony R.
Roman, Kristin
Dunn, Andrew
Cordover, David
Eterovic, Agda Karina
Liu, Jinsong
Burks, Jared K.
Baggerly, Keith A.
Fleming, Nicole D.
Lu, Karen H.
Westin, Shannon N.
Coleman, Robert L.
Mills, Gordon B.
Casablanca, Yovanni
Zhang, Jianhua
Conrads, Thomas P.
Maxwell, George L.
Futreal, P. Andrew
Sood, Anil K.
CELL REPORTS, 2020, 31 (02):

← 1 2 3 4 5 →